Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

The Lancet Oncology

Volumn 18, Issue 1, 2017, Pages 31-41

  Hellmann, Matthew D ^a   Rizvi, Naiyer A ^a   Goldman, Jonathan W ^b   Gettinger, Scott N ^c   Borghaei, Hossein ^d   Brahmer, Julie R ^e   Ready, Neal E ^f   Gerber, David E ^g   Chow, Laura Q ^h   Juergens, Rosalyn A ⁱ   Shepherd, Frances A ^j   Laurie, Scott A ^k   Geese, William J ^l   Agrawal, Shruti ^l   Young, Tina C ^l   Li, Xuemei ^l   Antonia, Scott J ^m  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c YALE CANCER CENTER   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

^k OTTAWA REGIONAL CANCER CENTRE   (Canada)

^l BRISTOL MYERS SQUIBB   (United States)

^m H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; CREATININE; IPILIMUMAB; NIVOLUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN DISEASE; CANCER STAGING; CATARACT; COHORT ANALYSIS; COLITIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DECREASED APPETITE; DEHYDRATION; DIABETES MELLITUS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENDOCRINE DISEASE; ESOPHAGITIS; FACIAL NERVE DISEASE; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPONATREMIA; INCREASED APPETITE; INFUSION RELATED REACTION; LIVER DISEASE; LUNG DISEASE; LUNG EMBOLISM; LYMPHOCYTE COUNT; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NON SMALL CELL LUNG CANCER; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RADIATION NECROSIS; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY DISTRESS; SIDE EFFECT; SKIN DISEASE; SKIN TOXICITY; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNITED STATES; VOMITING; ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 85007425840     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30624-6     Document Type: Article

References (32)

1. 1 Sandler, A, Gray, R, Perry, MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006), 2542–2550.
2. 2 Scagliotti, GV, Parikh, P, von Pawel, J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26 (2008), 3543–3551.
3. 3 Patel, JD, Socinski, MA, Garon, EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 31 (2013), 4349–4357.
4. 4 Reck, M, von Pawel, J, Zatloukal, P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27 (2009), 1227–1234.
5. 5 Paz-Ares, LG, de Marinis, F, Dediu, M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31 (2013), 2895–2902.
6. 6 Hodi, FS, O'Day, SJ, McDermott, DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
7. 7 Robert, C, Thomas, L, Bondarenko, I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364 (2011), 2517–2526.
8. 8 Robert, C, Long, GV, Brady, B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
9. 9 Motzer, RJ, Escudier, B, McDermott, DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
10. 10 Brahmer, JR, Reckamp, K, Baas, P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer. N Engl J Med 373 (2015), 123–135.
11. 11 Borghaei, H, Paz-Ares, L, Horn, L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
12. 12 Ansell, SM, Lesokhin, AM, Borrello, I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 (2015), 311–319.
13. 13 Gettinger, SN, Horn, L, Gandhi, L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33 (2015), 2004–2012.
14. 14 Okazaki, T, Chikuma, S, Iwai, Y, Fagarasan, S, Honjo, T, A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14 (2013), 1212–1218.
15. 15 Larkin, J, Chiarion-Sileni, V, Gonzalez, R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
16. 16 Postow, MA, Chesney, J, Pavlick, AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372 (2015), 2006–2017.
17. 17 Hodi, FS, Chesney, J, Pavlick, AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17 (2016), 1558–1568.
18. 18 Gettinger, SN, Rizvi, N, Chow, LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small cell lung cancer. J Clin Oncol 34 (2016), 2980–2987.
19. 19 Rizvi, NA, Hellmann, MD, Brahmer, JR, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non–small-cell lung cancer. J Clin Oncol 34 (2016), 2969–2979.
20. 20 Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
21. 21 Phillips, T, Simmons, P, Inzunza, HD, et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol 23 (2015), 541–549.
22. 22 Antonia, SJ, Gettinger, S, Goldman, JW, et al. Safety and efficacy of first-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 90:suppl (2014), S32–S33.
23. 23 Rizvi, NA, Gettinger, SN, Goldman, JW, et al. Safety and efficacy of first-line nivolumab (NIVO; anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC). J Thorac Oncol, 10, 2015, S176.
24. 24 Govindan, R, Ding, L, Griffith, M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150 (2012), 1121–1134.
25. 25 Rizvi, NA, Hellmann, MD, Snyder, A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in nonsmall cell lung cancer. Science 348 (2015), 124–128.
26. 26 Wolchok, JD, Kluger, H, Callahan, MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369 (2013), 122–133.
27. 27 Antonia, SJ, López-Martin, JA, Bendell, J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17 (2016), 883–895.
28. 28 Hammers, H, Plimack, ER, Infante, JR, et al. Expanded cohort results from CheckMate 016: a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol, 33(suppl), 2015 abstr 4516.
29. 29 Reck, M, Rodríguez-Abreu, D, Robinson, AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med, 2016 published online Oct 8. http://www.nejm.org/doi/full/10.1056/NEJMoa1606774.
30. 30 Antonia, S, Goldberg, SB, Balmanoukian, A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 17 (2016), 299–308.
31. 31 Gadgeel, S, Stevenson, J, Langer, C, et al. Pembrolizumab plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C. J Clin Oncol, 34(suppl), 2016 abstr 9016.
32. 32 Liu, SV, Powderly, JD, Camidge, DR, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 33(suppl), 2015 abstr 8030.